20.15
price down icon1.90%   -0.39
after-market After Hours: 20.15
loading
Castle Biosciences Inc stock is traded at $20.15, with a volume of 289.27K. It is down -1.90% in the last 24 hours and down -19.72% over the past month. Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
See More
Previous Close:
$20.54
Open:
$20.52
24h Volume:
289.27K
Relative Volume:
0.72
Market Cap:
$611.15M
Revenue:
$344.23M
Net Income/Loss:
$-24.16M
P/E Ratio:
-23.79
EPS:
-0.8471
Net Cash Flow:
$28.33M
1W Performance:
+5.33%
1M Performance:
-19.72%
6M Performance:
-46.81%
1Y Performance:
+26.81%
1-Day Range:
Value
$20.08
$20.91
1-Week Range:
Value
$18.48
$20.91
52-Week Range:
Value
$14.59
$44.28

Castle Biosciences Inc Stock (CSTL) Company Profile

Name
Name
Castle Biosciences Inc
Name
Phone
866-788-9007
Name
Address
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Name
Employee
942
Name
Twitter
@castlebio
Name
Next Earnings Date
2026-05-06
Name
Latest SEC Filings
Name
CSTL's Discussions on Twitter

Compare CSTL vs TMO, DHR, IDXX, WAT, A

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
CSTL icon
CSTL
Castle Biosciences Inc
20.15 622.98M 344.23M -24.16M 28.33M -0.8471
TMO icon
TMO
Thermo Fisher Scientific Inc
448.28 167.00B 45.20B 6.87B 6.75B 18.19
DHR icon
DHR
Danaher Corp
172.00 122.68B 24.78B 3.68B 5.29B 5.1743
IDXX icon
IDXX
Idexx Laboratories Inc
559.37 43.63B 4.45B 1.10B 1.06B 13.59
WAT icon
WAT
Waters Corp
342.37 33.48B 3.77B 449.25M 240.68M 7.8556
A icon
A
Agilent Technologies Inc
114.96 32.44B 7.07B 1.29B 993.00M 4.5355

Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-14-23 Initiated Guggenheim Buy
Jan-05-23 Initiated Scotiabank Sector Outperform
Jan-07-22 Initiated Stephens Overweight
Apr-30-21 Initiated Lake Street Buy
Nov-10-20 Initiated KeyBanc Capital Markets Overweight
Dec-27-19 Reiterated Canaccord Genuity Buy
Aug-19-19 Initiated BTIG Research Buy
Aug-19-19 Initiated Canaccord Genuity Buy
Aug-19-19 Initiated Robert W. Baird Outperform
Aug-19-19 Initiated SVB Leerink Outperform
View All

Castle Biosciences Inc Stock (CSTL) Latest News

pulisher
May 24, 2026

How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets - Yahoo! Finance Canada

May 24, 2026
pulisher
May 23, 2026

(CSTL) Volatility Zones as Tactical Triggers - Stock Traders Daily

May 23, 2026
pulisher
May 22, 2026

Castle Biosciences (CSTL) CEO reports planned stock sales and option exercises - Stock Titan

May 22, 2026
pulisher
May 22, 2026

Castle Biosciences, Inc.Common stock (NQ: CSTL - The Chronicle-Journal

May 22, 2026
pulisher
May 21, 2026

Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable - MSN

May 21, 2026
pulisher
May 21, 2026

Castle Biosciences, Inc. $CSTL Shares Sold by UBS Group AG - MarketBeat

May 21, 2026
pulisher
May 15, 2026

Portolan Capital amends Castle Biosciences (NASDAQ: CSTL) 13G; 4.45% stake reported - Stock Titan

May 15, 2026
pulisher
May 15, 2026

RTW Funds own 2.76M Castle Biosciences shares (CSTL) — 9.3% stake - Stock Titan

May 15, 2026
pulisher
May 14, 2026

A Look at Castle Biosciences Inc (CSTL) After 4.1% Gain -- GF Va - GuruFocus

May 14, 2026
pulisher
May 14, 2026

Winner of My Stock-Picking Derby Sold Her Top Pick Too Soon - Investing.com

May 14, 2026
pulisher
May 13, 2026

Castle Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CSTL) 2026-05-13 - Seeking Alpha

May 13, 2026
pulisher
May 13, 2026

META_TITLE_QUOTE - Yahoo Finance

May 13, 2026
pulisher
May 13, 2026

CSTL Maintained by BTIG -- Price Target Lowered to $40.00 - GuruFocus

May 13, 2026
pulisher
May 13, 2026

BTIG lowers Castle Biosciences stock price target on higher costs By Investing.com - Investing.com India

May 13, 2026
pulisher
May 13, 2026

BTIG Research Has Lowered Expectations for Castle Biosciences (NASDAQ:CSTL) Stock Price - MarketBeat

May 13, 2026
pulisher
May 13, 2026

BTIG lowers Castle Biosciences stock price target on higher costs - Investing.com UK

May 13, 2026
pulisher
May 13, 2026

Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference - PR Newswire

May 13, 2026
pulisher
May 13, 2026

BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40 - Moomoo

May 13, 2026
pulisher
May 12, 2026

Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Bre - GuruFocus

May 12, 2026
pulisher
May 12, 2026

Castle Biosciences recognized for driving progress in global healthcare with AdvanceAD-Tx accolade - Traders Union

May 12, 2026
pulisher
May 12, 2026

Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation - PR Newswire

May 12, 2026
pulisher
May 12, 2026

Price-Driven Insight from (CSTL) for Rule-Based Strategy - Stock Traders Daily

May 12, 2026
pulisher
May 12, 2026

TradingKey - TradingKey

May 12, 2026
pulisher
May 11, 2026

Derek Maetzold, Castle Biosciences CEO, sells $217,904 in shares By Investing.com - Investing.com Australia

May 11, 2026
pulisher
May 11, 2026

Derek Maetzold, Castle Biosciences CEO, sells $217,904 in shares - Investing.com India

May 11, 2026
pulisher
May 11, 2026

Castle Biosciences (CSTL) CEO sells shares and exercises stock options in pre-planned trades - Stock Titan

May 11, 2026
pulisher
May 09, 2026

Castle Biosciences (NASDAQ:CSTL) Cut to "Sell" at Wall Street Zen - MarketBeat

May 09, 2026
pulisher
May 08, 2026

Castle Biosciences, Inc. (CSTL) Stock Analysis: A Promising 145.58% Upside Potential - DirectorsTalk Interviews

May 08, 2026
pulisher
May 07, 2026

CSTL Achieves Strong Q1 Revenue, Raises 2026 Guidance - GuruFocus

May 07, 2026
pulisher
May 07, 2026

CSTL Maintained by Baird -- Price Target Lowered to $43 - GuruFocus

May 07, 2026
pulisher
May 07, 2026

Wall Street analysts predict an 85.15% upside in Castle Biosciences (CSTL): Here's what you should know - MSN

May 07, 2026
pulisher
May 07, 2026

Derek Maetzold files Form 144 to sell CSTL (NASDAQ: CSTL) shares - Stock Titan

May 07, 2026
pulisher
May 07, 2026

Castle Biosciences Down Over 15%, on Pace for Largest Percent Decrease Since July 2024 -- Data Talk - Moomoo

May 07, 2026
pulisher
May 07, 2026

Castle Biosciences (NASDAQ:CSTL) Shares Gap Down Following Analyst Downgrade - MarketBeat

May 07, 2026
pulisher
May 07, 2026

CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40 - Moomoo

May 07, 2026
pulisher
May 07, 2026

Castle Biosciences Q1 2026 slides: revenue beats, guidance raised By Investing.com - Investing.com Australia

May 07, 2026
pulisher
May 07, 2026

Castle Biosciences (NASDAQ:CSTL) Price Target Lowered to $43.00 at Robert W. Baird - MarketBeat

May 07, 2026
pulisher
May 07, 2026

Castle Biosciences targets $345M-$355M 2026 revenue as TissueCypher volumes grow 58% and AdvanceAD-Tx reaches ~650 orders - MSN

May 07, 2026
pulisher
May 06, 2026

Castle Biosciences (NASDAQ:CSTL) Releases Earnings Results, Hits Expectations - MarketBeat

May 06, 2026
pulisher
May 06, 2026

Castle Biosciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

May 06, 2026
pulisher
May 06, 2026

Castle Biosciences Q1 Earnings Call Highlights - MarketBeat

May 06, 2026
pulisher
May 06, 2026

CSTL: Strong Q1 2026 results with raised guidance, record test volumes, and improved financials - TradingView

May 06, 2026
pulisher
May 06, 2026

Castle (CSTL) Q1 2026 Earnings Transcript - AOL.com

May 06, 2026
pulisher
May 06, 2026

Earnings call transcript: Castle Biosciences Q1 2026 sees revenue growth By Investing.com - Investing.com Australia

May 06, 2026
pulisher
May 06, 2026

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance

May 06, 2026
pulisher
May 06, 2026

Castle Biosciences Q1 2026 slides: revenue beats, guidance raised - Investing.com

May 06, 2026
pulisher
May 06, 2026

Earnings call transcript: Castle Biosciences Q1 2026 sees revenue growth - Investing.com

May 06, 2026

Castle Biosciences Inc Stock (CSTL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
DGX DGX
$195.21
price up icon 0.72%
$144.41
price down icon 0.29%
MTD MTD
$1,103.09
price up icon 1.16%
IQV IQV
$167.90
price down icon 0.07%
$203.19
price down icon 0.25%
A A
$114.96
price up icon 0.15%
Cap:     |  Volume (24h):